132 related articles for article (PubMed ID: 11897602)
1. In vitro activities of peptide deformylase inhibitors against gram-positive pathogens.
Wise R; Andrews JM; Ashby J
Antimicrob Agents Chemother; 2002 Apr; 46(4):1117-8. PubMed ID: 11897602
[TBL] [Abstract][Full Text] [Related]
2. Comparative antimicrobial characterization of LBM415 (NVP PDF-713), a new peptide deformylase inhibitor of clinical importance.
Fritsche TR; Sader HS; Cleeland R; Jones RN
Antimicrob Agents Chemother; 2005 Apr; 49(4):1468-76. PubMed ID: 15793128
[TBL] [Abstract][Full Text] [Related]
3. In vitro activities of nine peptide deformylase inhibitors and five comparator agents against respiratory and skin pathogens.
Bowker KE; Noel AR; MacGowan AP
Int J Antimicrob Agents; 2003 Dec; 22(6):557-61. PubMed ID: 14659651
[TBL] [Abstract][Full Text] [Related]
4. Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents.
Apfel C; Banner DW; Bur D; Dietz M; Hirata T; Hubschwerlen C; Locher H; Page MG; Pirson W; Rossé G; Specklin JL
J Med Chem; 2000 Jun; 43(12):2324-31. PubMed ID: 10882358
[TBL] [Abstract][Full Text] [Related]
5. Antimicrobial spectrum and activity of NVP PDF-713, a novel peptide deformylase inhibitor, tested against 1,837 recent Gram-positive clinical isolates.
Jones RN; Fritsche TR; Sader HS
Diagn Microbiol Infect Dis; 2004 May; 49(1):63-5. PubMed ID: 15135503
[TBL] [Abstract][Full Text] [Related]
6. Peptide deformylase inhibitors with activity against respiratory tract pathogens.
East SP; Beckett RP; Brookings DC; Clements JM; Doel S; Keavey K; Pain G; Smith HK; Thomas W; Thompson AJ; Todd RS; Whittaker M
Bioorg Med Chem Lett; 2004 Jan; 14(1):59-62. PubMed ID: 14684298
[TBL] [Abstract][Full Text] [Related]
7. AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States.
Pfaller MA; Farrell DJ; Sader HS; Jones RN
Clin Infect Dis; 2012 Sep; 55 Suppl 3():S187-93. PubMed ID: 22903951
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
Watters AA; Jones RN; Leeds JA; Denys G; Sader HS; Fritsche TR
J Antimicrob Chemother; 2006 May; 57(5):914-23. PubMed ID: 16549511
[TBL] [Abstract][Full Text] [Related]
9. Structure-based design of a macrocyclic inhibitor for peptide deformylase.
Hu X; Nguyen KT; Verlinde CL; Hol WG; Pei D
J Med Chem; 2003 Aug; 46(18):3771-4. PubMed ID: 12930137
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections.
Fritsche TR; Kirby JT; Jones RN
Diagn Microbiol Infect Dis; 2004 Jul; 49(3):201-9. PubMed ID: 15246511
[TBL] [Abstract][Full Text] [Related]
11. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Jones RN; Sader HS; Fritsche TR; Pottumarthy S
Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
[TBL] [Abstract][Full Text] [Related]
12. Quality control guidelines for MIC susceptibility testing of NVP PDF-713: a novel peptide deformylase inhibitor.
Anderegg TR; Biedenbach DJ; Jones RN;
Int J Antimicrob Agents; 2003 Jul; 22(1):84-6. PubMed ID: 12842335
[No Abstract] [Full Text] [Related]
13. Potential utility of a peptide deformylase inhibitor (NVP PDF-713) against oxazolidinone-resistant or streptogramin-resistant Gram-positive organism isolates.
Jones RN; Moet GJ; Sader HS; Fritsche TR
J Antimicrob Chemother; 2004 May; 53(5):804-7. PubMed ID: 15056649
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and antibacterial activity of peptide deformylase inhibitors.
Huntington KM; Yi T; Wei Y; Pei D
Biochemistry; 2000 Apr; 39(15):4543-51. PubMed ID: 10758004
[TBL] [Abstract][Full Text] [Related]
15. In vitro activities of BAY Y3118, ciprofloxacin, ofloxacin, and fleroxacin against gram-positive and gram-negative pathogens from respiratory tract and soft tissue infections.
Bongaerts GP; Hoogkamp-Korstanje JA
Antimicrob Agents Chemother; 1993 Sep; 37(9):2017-9. PubMed ID: 8239624
[TBL] [Abstract][Full Text] [Related]
16. Peptide deformylase as an antibacterial drug target: target validation and resistance development.
Apfel CM; Locher H; Evers S; Takács B; Hubschwerlen C; Pirson W; Page MG; Keck W
Antimicrob Agents Chemother; 2001 Apr; 45(4):1058-64. PubMed ID: 11257016
[TBL] [Abstract][Full Text] [Related]
17. Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents.
Peric M; Browne FA; Jacobs MR; Appelbaum PC
Clin Ther; 2003 Jan; 25(1):169-77. PubMed ID: 12637118
[TBL] [Abstract][Full Text] [Related]
18. Antibiotic activity and characterization of BB-3497, a novel peptide deformylase inhibitor.
Clements JM; Beckett RP; Brown A; Catlin G; Lobell M; Palan S; Thomas W; Whittaker M; Wood S; Salama S; Baker PJ; Rodgers HF; Barynin V; Rice DW; Hunter MG
Antimicrob Agents Chemother; 2001 Feb; 45(2):563-70. PubMed ID: 11158755
[TBL] [Abstract][Full Text] [Related]
19. Comparative in vitro activity of ertapenem against bacterial pathogens isolated from patients with lower respiratory tract infections.
Hicks PS; Pelak B; Woods GL; Bartizal KF; Motyl M
Clin Microbiol Infect; 2002 Nov; 8(11):753-7. PubMed ID: 12445016
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of a new antibiotic, NVP-PDF386 (VRC4887), against Chlamydia pneumoniae.
Roblin PM; Hammerschlag MR
Antimicrob Agents Chemother; 2003 Apr; 47(4):1447-8. PubMed ID: 12654690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
